ArticleCancer biotherapy & radiopharmaceuticals2017

Beyond Dose: Using Pretherapy Biomarkers to Improve Dose Prediction of Outcomes for Radioimmunotherapy of Non-Hodgkin Lymphoma.

Peter L Roberson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.